Alector Appoints Dr. Arnon Rosenthal as CSO

Ticker: ALEC · Form: 8-K · Filed: 2025-01-10T00:00:00.000Z

Sentiment: neutral

Topics: management-change, executive-appointment, biotech

TL;DR

Alector just hired a new CSO, Dr. Arnon Rosenthal, to lead their neurodegenerative disease research.

AI Summary

On January 9, 2025, Alector, Inc. announced the appointment of Dr. Arnon Rosenthal as Chief Scientific Officer. Dr. Rosenthal brings extensive experience in neurodegenerative disease research and drug development to Alector. This appointment is expected to bolster Alector's scientific leadership as it advances its pipeline of therapies for neurodegenerative diseases.

Why It Matters

The appointment of a new Chief Scientific Officer with deep expertise in neurodegenerative diseases signals a strategic focus on advancing Alector's drug development pipeline in this critical area.

Risk Assessment

Risk Level: medium — The appointment of a new CSO is a significant leadership change that could impact the company's strategic direction and research progress.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Scientific Officer at Alector, Inc.?

Dr. Arnon Rosenthal has been appointed as the new Chief Scientific Officer.

What is the effective date of this report?

The earliest event reported is dated January 09, 2025.

What is Alector, Inc.'s primary business focus?

Alector, Inc. is focused on Biological Products, specifically in the area of neurodegenerative diseases.

What is Alector, Inc.'s principal executive office address?

Alector, Inc.'s principal executive offices are located at 131 Oyster Point Blvd., Suite 600, South San Francisco, California 94080.

What is Alector, Inc.'s telephone number?

Alector, Inc.'s telephone number is (415) 231-5660.

From the Filing

0000950170-25-003811.txt : 20250110 0000950170-25-003811.hdr.sgml : 20250110 20250110080009 ACCESSION NUMBER: 0000950170-25-003811 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20250109 ITEM INFORMATION: Other Events FILED AS OF DATE: 20250110 DATE AS OF CHANGE: 20250110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alector, Inc. CENTRAL INDEX KEY: 0001653087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822933343 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38792 FILM NUMBER: 25520492 BUSINESS ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-231-5660 MAIL ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Alector LLC DATE OF NAME CHANGE: 20150915 8-K 1 alec-20250109.htm 8-K 8-K 0001653087 false 0001653087 2025-01-09 2025-01-09   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2025     Alector, Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-38792 82-2933343 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           131 Oyster Point Blvd. Suite 600   South San Francisco , California   94080 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (415) 231-5660     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock   ALEC   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 8.01 Other Events. Alector, Inc. (the “Company”) was developing AL002, its TREM2 program asset, to treat patients with early Alzheimer’s disease (AD) in collaboration with AbbVie Biotechnology, Ltd. (“AbbVie”) under the Co-Development and Option Agreement, dated as of October 16, 2017, between the parties, as amended on February 13, 2023 (the “AbbVie Agreement”). As announced on November 25, 2024, the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early AD did not meet its primary endpoint. On January 9, 2025, AbbVie provided written notice to the Company terminating the TREM2 program. As that program is

View on Read The Filing